Disease Landscape and Forecast Insights

The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…

Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…

Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…

The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…

In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…

In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…

In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3…

In 2023, sales of branded biologics in immunology exceeded $64 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

In 2023, sales of branded biologics for oncology, immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $150 billion in the major pharmaceutical…